Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Get Instant Summarized Text (Gist) A new transcatheter valve, the Trilogy system, has demonstrated safety and efficacy in treating aortic regurgitation, with a one-year mortality rate of 8.1% ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Zydus Medtech, a subsidiary of Zydus Lifesciences, has entered into a global licensing agreement with Brazilian medical ...

Anteris Technologies Global Corp.’s AVR share price has dipped by 5.20%, which has investors questioning if this is right ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence ...

The company is rapidly expanding its interventional cardiology portfolio, and under the partnership will commercialize the ...